The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have shown that DPP4i exhibit cardiovascular neutrality in T2DM patients.”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across the trials of this drug class, there appears to be no interaction by age-group (110-112).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]
The cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [313]
The cited source says what the claim attributes to it.
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [19]
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [31]
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [215]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“In mice, GLP-1 causes vasodilation through both GLP-1 receptor-dependent and -independent mechanisms.211”
From The Vasculature in Prediabetes (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,006
Fu, A. Z., Johnston, S. S., Ghannam, A. F., Tsai, K., Cappell, K. A., Fowler, R., Riehle, E., Cole, A. L., Kalsekar, I. D., & Sheehan, J. J. (2016) · Diabetes Care · doi:10.2337/dc15-0764 · Cited by 79
SGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. M., & Inzucchi, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0943-4 · Cited by 80
Worsening Heart Failure During the Use of DPP-4 Inhibitors
Packer, M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2017.12.016 · Cited by 78
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 80
Hiruma, S., Shigiyama, F., Hisatake, S., Mizumura, S., Shiraga, N., Hori, M., Ikeda, T., Hirose, T., & Kumashiro, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01228-3 · Cited by 80
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 80
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 79
High glucose–induced endothelial progenitor cell dysfunction
Kang, H., Ma, X., Liu, J., Fan, Y., & Deng, X. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117719058 · Cited by 79
Al-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
Davies, M. J., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 78
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
Meagher, P., Adam, M., Civitarese, R., Bugyei‐Twum, A., & Connelly, K. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.026 · Cited by 79
Åhrén, B., & Foley, J. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3899-2 · Cited by 77
Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1778 · Cited by 76
Self-citationYamada, H., Tanaka, A., Kusunose, K., Amano, R., Matsuhisa, M., Daida, H., Ito, M., Tsutsui, H., Nanasato, M., Kamiya, H., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0546-2 · Cited by 76
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 80
Cancer Biology and Prevention in Diabetes
Srivastava, S. P., & Goodwin, J. E. (2020) · Cells · doi:10.3390/cells9061380 · Cited by 77
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 75
Irace, C., Casciaro, F., Scavelli, F. B., Oliverio, R., Cutruzzolà, A., Cortese, C., & Gnasso, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0695-y · Cited by 74
Current perspectives on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0456-8 · Cited by 73
Self-citationBell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 75
Pagidipati, N. J., Zheng, Y., Green, J. B., McGuire, D. K., Mentz, R. J., Shah, S. H., Aschner, P. J., Delibaşı, T., Rodbard, H. W., Westerhout, C. M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.09.016 · Cited by 73
Self-citationLevelt, E., Gulsin, G. S., Neubauer, S., & McCann, G. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0724 · Cited by 76
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., & Chaiyakunapruk, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.146 · Cited by 72
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 76
Marx, N., McGuire, D. K., Perkovic, V., Woerle, H., Broedl, U. C., von Eynatten, M., George, J. T., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dc17-0068 · Cited by 73
Self-citationCardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 73
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 72
Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
Ou, H., Chang, K., Li, C., & Wu, J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0350-4 · Cited by 72
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 72
Cardiovascular Protection in People With Diabetes
Stone, J. A., Houlden, R. L., Lin, P., Udell, J. A., & Verma, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.024 · Cited by 74
Svanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 72
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2
Maranta, F., Cianfanelli, L., & Cianflone, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_514 · Cited by 74
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.012 · Cited by 74
Chang, C., Yeh, Y., Chan, Y., Liu, J., Chang, S., Lee, H., Wu, L., Yen, K., Kuo, C.-T., & See, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0640-5 · Cited by 73
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 72
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70
Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 71
Savarese, G., D’Amore, C., Federici, M., Martino, F. D., Dellegrottaglie, S., Marciano, C., Ferrazzano, F., Losco, T., Lund, L. H., Trimarco, B., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.208 · Cited by 71
Liu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Prattichizzo, F., Sala, L. L., Rydén, L., Marx, N., Ferrini, M., Valensi, P. E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880040 · Cited by 70
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 73
Medical Management of Diabesity: Do We Have Realistic Targets?
Pappachan, J. M., & Viswanath, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0828-9 · Cited by 73
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Self-citationZhao, M. H., Chen, J., Yuan, Y., Zou, Z., Lai, X., Rahmani, D. M., Wang, F., Yang, X., Huang, Q., & Bu, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-07921-2 · Cited by 71
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic
King, R., & Grant, P. J. (2016) · Herz · doi:10.1007/s00059-016-4414-8 · Cited by 71
Oyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., Kamiya, H., Ajioka, M., Ishihara, M., Dai, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002051 · Cited by 68
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
Cardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 67
Pujadas, G., Nigris, V. D., Prattichizzo, F., Sala, L. L., Testa, R., & Ceriello, A. (2016) · Endocrine · doi:10.1007/s12020-016-1052-0 · Cited by 67
Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K. A., Alkayyali, S., Brøns, C., Forsblom, C. M., Jonsson, A. E., et al. (2015) · Diabetes · doi:10.2337/db15-0122 · Cited by 68
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 68
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 67
Roussel, R., Steg, P. G., Mohammedi, K., Marre, M., & Potier, L. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13033 · Cited by 66
Carbone, S., Billingsley, H., Canada, J. M., Bressi, E., Rotelli, B., Kadariya, D., Dixon, D. L., Markley, R., Trankle, C. R., Cooke, R. H., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3335 · Cited by 66
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Weng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T. (2019) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.76 · Cited by 65
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 67
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, C., & Marx, N. (2018) · Diabetologia · doi:10.1007/s00125-018-4678-z · Cited by 65
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J., Montastruc, F., Platt, R. W., Bouganim, N., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4880 · Cited by 66
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Williams, D. M., Nawaz, A., & Evans, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00747-3 · Cited by 68
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 68
Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
Bekiari, E., Rizava, C., Athanasiadou, E. A., Papatheodorou, K., Liakos, A., Karagiannis, T., Mainou, M., Rika, M., Boura, P., & Τσάπας, Α. (2015) · Endocrine · doi:10.1007/s12020-015-0841-1 · Cited by 64
Novel Therapies for Acute Kidney Injury
Chen, H., & Busse, L. W. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.06.020 · Cited by 65
Abdul-Ghani, M. A., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 64
Regier, E. E., Venkat, M. V., & Close, K. L. (2016) · Clinical Diabetes · doi:10.2337/cd16-0005 · Cited by 63
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 69
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 69
White, W. B., Kupfer, S., Zannad, F. M., Mehta, C. R., Wilson, C., Lei, L., Bakris, G. L., Nissen, S. E., Cushman, W. C., Heller, S. R., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0303 · Cited by 64
Rozentsvit, A., Vinokur, K., Samuel, S., Li, Y., Gerdes, A. M., & Carrillo-Sepúlveda, M. A. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485448 · Cited by 65
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
Badjatiya, A., Merrill, P., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., Hernandez, A. F., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008018 · Cited by 63
Self-citationPerkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
Self-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Arab, H. H., Gad, A. M., Reda, E., Yahia, R., & Eid, A. H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119031 · Cited by 62
Diabetic Proteinuria Revisited: Updated Physiologic Perspectives
Heyman, S. N., Raz, I., Dwyer, J. P., Sibony, R. W., Lewis, J. B., & Abassi, Z. A. (2022) · Cells · doi:10.3390/cells11182917 · Cited by 65
Abbas, A. S., Dehbi, H., & Ray, K. K. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12595 · Cited by 62
Singh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 63
Sitagliptin and risk of fractures in type 2 diabetes: R esults from the TECOS trial
Josse, R. G., Majumdar, S. R., Zheng, Y., Adler, A., Bethel, M. A., Buse, J. B., Green, J. B., Kaufman, K. D., Rodbard, H. W., Tankova, T. I., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12786 · Cited by 62
Self-citationPancreatic Safety of Sitagliptin in the TECOS Study
Buse, J. B., Bethel, M. A., Green, J. B., Stevens, S. R., Lokhnygina, Y. V., Aschner, P. J., Grado, C. A. R., Tankova, T. I., Wainstein, J., Josse, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2780 · Cited by 62
Self-citationVerma, S., Goldenberg, R., Bhatt, D. L., Farkouh, M. E., Quan, A., Teoh, H., Connelly, K. A., Leiter, L. A., & Friedrich, J. O. (2017) · CMAJ Open · doi:10.9778/cmajo.20160058 · Cited by 63
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 65
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes
Zhang, X., & Zhao, Q. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000782 · Cited by 62
Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 63
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 62
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus
Pagidipati, N. J., Návar, A. M., Pieper, K. S., Green, J. B., Bethel, M. A., Armstrong, P. W., Josse, R. G., McGuire, D. K., Lokhnygina, Y. V., Cornel, J. H., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.027252 · Cited by 61
Self-citationvan Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 63
Bae, J. H., Kim, S., Park, E.-G., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.80 · Cited by 62
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 61
Bethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., de Werf, F. V., McGuire, D. K., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1135 · Cited by 62
Self-citationImpact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 61
Metadata
- Authors
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Oxford (GB)
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- The University of Texas Southwestern Medical Center (US)
- Helmholtz Munich (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 232-242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142830692
- Semantic Scholar
- 5f5aabad35a6c6137b19d8640d5d6cafc91815e5
- Cited by
- 2,577
- References
- 16
- Citations by year
- 2026: 68 · 2025: 121 · 2024: 120 · 2023: 139 · 2022: 170 · 2021: 210 · 2020: 289 · 2019: 267 · 2018: 343 · 2017: 343 · 2016: 378 · 2015: 120
- FWCI
- 341.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by-nc-nd)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- South Australian Health and Medical Research Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sitagliptin, type 2 diabetes, cardiovascular disease, DPP-4 inhibitors, major adverse cardiovascular events, heart failure hospitalization, acute pancreatitis, pancreatic cancer, HbA1c, glycemic control, non-inferiority
- MeSH terms
- Sitagliptin Phosphate, Administration, Oral, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Heart Diseases, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Pyrazines, Triazoles, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
